To assess the association between TFF3 promoter methylation levels and PC aggressiveness, we compared DNA methylation levels with standard clinicopathological variables: age at diagnosis, pre-operative PSA level, Gleason score, pathological tumor (pT)-stage, pathological lymph node (pN)-stage, surgical margin, and PSA recurrence status in our large RP cohort (n = 292; Table 1). The gene discussed is TFF3; the disease is pachyonychia congenita.